Beijing Boren Hospital

Running trials

• Recruiting

  LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

  NCT07100067· Source

• Recruiting

  A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

  NCT06980597· Phase 1· Source

• Active, not recruiting

  A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

  NCT05716087· Phase 2· Source

• Recruiting

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236· Phase 3· Source

• Recruiting

  Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT04684147· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• ANCA-associated vasculitis1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

  NCT05376345· Phase 1· Source

• Withdrawn

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Phase 1· Source

• Completed

  Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

  NCT04325841· Phase 2· Source

• Withdrawn

  Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

  NCT05248685· Phase 1· Source

• Completed

  Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

  NCT04689659· Phase 2· Source

• Terminated

  Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

  NCT05032599· Phase 1· Source

• Terminated

  Study of Sequential CAR-T Cell Treating Leukemia Children

  NCT04340154· Phase 2· Source

• Completed

  Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

  NCT04340167· Phase 2· Source

• Completed

  A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT04202003· Phase 1/2· Source